1 Binary toxin expression by *Clostridioides difficile* is associated with worse disease

- 2 Mary K. Young¹, Jhansi L. Leslie¹, Gregory R. Madden¹, David M. Lyerly², Robert J. Carman²,
- 3 David B. Stewart³, Mayuresh M. Abhyankar¹, William A. Petri Jr.^{1, 4, 5, #}
- 4 ¹Division of Infectious Diseases and International Health, Department of Medicine, University of
- 5 Virginia Health System, Charlottesville, Virginia, USA
- 6 ²TechLab Inc, Blacksburg, Virginia, USA
- ³Department of Surgery, Southern Illinois University School of Medicine, Springfield, Illinois,
- 8 USA
- ⁴Department of Microbiology, Immunology and Cancer Biology, University of Virginia School of
- 10 Medicine, Charlottesville, Virginia, USA
- ⁵Department of Pathology, University of Virginia School of Medicine, Charlottesville, Virginia,
- 12 USA
- 13 [#]Corresponding Author
- 14 William A. Petri Jr.
- 15 PO Box 801340
- 16 Charlottesville, VA 22908
- 17 Telephone: 434-924-5621
- 18 Fax: 434-924-0075
- 19 Email: wap3g@virginia.edu
- 20
- 21 Key words: C. difficile, CDT, binary toxin, CDI, ribotype 027
- 22 **Running title:** CDT in stool associated with worse disease
- 23 Summary: We found that CDI patients with CDT detected in stool by immunoassay were more
- 24 likely to have severe disease and had higher 90-day mortality.

25

27 Abstract

28	Background. The incidence of Clostridioides difficile infection (CDI) has increased over the past
29	two decades and is considered an urgent threat by the Centers for Disease Control.
30	Hypervirulent strains such as ribotype 027, that possess genes for an additional toxin C. difficile
31	binary toxin (CDT) are contributing to increased morbidity and mortality. In the mouse model,
32	CDT activates Toll-like receptor 2 resulting in suppression of a protective type 2 innate immune
33	response mediated by eosinophils.
34	Methods. We retrospectively tested stool from 215 CDI patients for CDT by enzyme-linked
35	immunosorbent assay (ELISA). Stratifying patients by CDT status, we assessed if disease severity
36	and clinical outcomes correlated with CDT positivity. Additionally, we performed 16 S rRNA
37	gene sequencing to examine if CDT positive samples had an altered fecal microbiota.
38	Results . We found that patients with CdtB, the pore forming component of CDT, detected in
39	their stool were more likely to have severe disease and had higher 90-day mortality compared
40	to CDT negative patients. CDT positive patients also had higher <i>C. difficile</i> bacterial burden and
41	white blood cell counts. There was no significant difference in gut microbiome diversity
42	between CDT positive and negative patients.
43	Conclusions . Patients with fecal samples that were positive for CDT had increased disease
44	severity and worse clinical outcomes. Utilization of PCR and <i>C. difficile</i> Toxins A and B testing
45	may not reveal the entire picture when diagnosing CDI and the detection of CDT-expressing
46	strains may be valuable during patient treatment.
47	

49 Introduction

50	<i>Clostridioides difficile</i> (<i>C. difficile</i>) is a gram-positive, spore-forming bacteria that can cause
51	diarrhea and colitis in patients with dysbiosis. In 2017, C. difficile infection (CDI) affected over
52	200,000 people a year, resulting in almost 13,000 deaths and was considered an urgent
53	antibiotic resistant threat by the Centers for Disease Control (1). The increased prevalence of
54	CDI is attributed to novel hypervirulent strains that cause worse disease and higher mortality
55	(2). In addition to the main virulence factors, toxins A and B, these hypervirulent strains
56	produce a third toxin known as <i>C. difficile</i> binary toxin (CDT) or binary toxin. CDT is comprised of
57	CdtA, an actin-specific ADP-ribosyl transferase, and CdtB, the receptor-binding component (3).
58	Our lab has shown that in a mouse model, CDT induces Toll-like receptor 2 (TLR2) pathways
59	resulting in increased host inflammation and suppressed protective eosinophils (4).
60	With the increased prevalence of CDI in the United States, there has been substantial debate
61	over the optimal diagnostic approach (5). The use of highly sensitive polymerase chain reaction
62	(PCR) (that detects the presence of <i>C. difficile</i> but not toxin production) and increased clinical
63	testing of asymptomatic individuals is believed to contribute to the overdiagnosis of CDI (6-8).
64	While PCR positive, toxin A/B enzyme immunoassay (EIA) positive patients have increased
65	disease severity compared to patients with discordant tests (PCR-, toxin A/B EIA+), fatal
66	infections may occur even in the absence of detectable toxins A/B (8-10). It is uncommon for <i>C</i> .
67	difficile strains to be ribotyped or tested for CDT-encoded genes, leading to insufficient
68	information on potential prognosis. Previous studies have shown that detection of CDT genes in
69	stool by PCR has been associated with worse outcomes, but no investigation has been done to
70	compare disease severity and toxin detection by immunoassay (2, 11, 12).

71	Although little has been published on expressed CDT in stool, Carman et al (2018) showed that
72	027, by far the most dominant of the CDT-producing ribotypes, was about 10-fold more
73	abundant in patient feces than was 014/020 and made about 10-fold more TcdA and TcdB than
74	014/020. Ribotype 014/020 is a non-CDT producer and probably the most widespread and
75	abundant ribotype before the emergence of fluoroquinolone resistance, notably in 027.
76	Furthermore 027 infection resulted in about a five-fold increase in fecal lactoferrin compared
77	with 014/020 (13). In this study, we wished to further explore the relationship between CDT
78	and disease severity by testing for toxin in stool with enzyme-linked immunosorbent assay
79	(ELISA). We found that CDI patients with CDT-expressing strains had increase disease severity
80	and worse clinical outcomes.
81	
82	Methods
82 83	Methods Sample Collection and Patient Information
82 83 84	Methods Sample Collection and Patient Information Stool collected from 215 CDI patients were retrospectively identified from the University of
82 83 84 85	Methods Sample Collection and Patient Information Stool collected from 215 CDI patients were retrospectively identified from the University of Virginia (UVA) Medical Center's electronic medical records (EMR). Stool samples were collected
82 83 84 85 86	MethodsSample Collection and Patient InformationStool collected from 215 CDI patients were retrospectively identified from the University ofVirginia (UVA) Medical Center's electronic medical records (EMR). Stool samples were collectedbetween 2015-2017 and were held in the clinical laboratory at 4°C for 48 hours, then aliquoted
82 83 84 85 86 87	MethodsSample Collection and Patient InformationStool collected from 215 CDI patients were retrospectively identified from the University ofVirginia (UVA) Medical Center's electronic medical records (EMR). Stool samples were collectedbetween 2015-2017 and were held in the clinical laboratory at 4°C for 48 hours, then aliquotedand stored at -80°C until testing. All patients had diarrhea and were positive for <i>C. difficile</i> by
82 83 84 85 86 87 88	MethodsSample Collection and Patient InformationStool collected from 215 CDI patients were retrospectively identified from the University ofVirginia (UVA) Medical Center's electronic medical records (EMR). Stool samples were collectedbetween 2015-2017 and were held in the clinical laboratory at 4°C for 48 hours, then aliquotedand stored at -80°C until testing. All patients had diarrhea and were positive for <i>C. difficile</i> byXpert <i>C. difficile</i> PCR (Cepheid, Sunnyvale, CA). Data on the presence or absence of CDT genes
82 83 84 85 86 87 88 88	MethodsSample Collection and Patient InformationStool collected from 215 CDI patients were retrospectively identified from the University ofVirginia (UVA) Medical Center's electronic medical records (EMR). Stool samples were collectedbetween 2015-2017 and were held in the clinical laboratory at 4°C for 48 hours, then aliquotedand stored at -80°C until testing. All patients had diarrhea and were positive for <i>C. difficile</i> byXpert <i>C. difficile</i> PCR (Cepheid, Sunnyvale, CA). Data on the presence or absence of CDT geneswas not collected, nor were isolates collected for typing. Patient demographics, clinical lab
82 83 84 85 86 87 88 88 89 90	MethodsSample Collection and Patient InformationStool collected from 215 CDI patients were retrospectively identified from the University ofVirginia (UVA) Medical Center's electronic medical records (EMR). Stool samples were collectedbetween 2015-2017 and were held in the clinical laboratory at 4°C for 48 hours, then aliquotedand stored at -80°C until testing. All patients had diarrhea and were positive for <i>C. difficile</i> byXpert <i>C. difficile</i> PCR (Cepheid, Sunnyvale, CA). Data on the presence or absence of CDT geneswas not collected, nor were isolates collected for typing. Patient demographics, clinical labresults and disease outcomes were collected retrospectively from UVA Clinical Data Repository
82 83 84 85 86 87 88 89 90 91	MethodsSample Collection and Patient InformationStool collected from 215 CDI patients were retrospectively identified from the University ofVirginia (UVA) Medical Center's electronic medical records (EMR). Stool samples were collectedbetween 2015-2017 and were held in the clinical laboratory at 4°C for 48 hours, then aliquotedand stored at -80°C until testing. All patients had diarrhea and were positive for <i>C. difficile</i> byXpert <i>C. difficile</i> PCR (Cepheid, Sunnyvale, CA). Data on the presence or absence of CDT geneswas not collected, nor were isolates collected for typing. Patient demographics, clinical labresults and disease outcomes were collected retrospectively from UVA Clinical Data Repositoryand the EMR. The collection of patient data was approved by the institutional review board

93 CdtB Detection

- 94 Stool samples from 215 patients were tested using a previously described research-only ELISA
- 95 for *Clostridium difficile* CdtB (14).

96 C. difficile TcdA and TcdB Detection

- 97 All stool samples were tested for **TcdA and TcdB** by C. DIFFICILE TOX A/B II[™] according to
- 98 manufacturer instructions (catalog no. T5015, TechLab Inc, Blacksburg, VA).

99 Lactoferrin Detection

- 100 Stool lactoferrin was assayed using LACTOFERRIN SCAN® according to manufacturer
- 101 instructions (catalog no. T5009 / 30351, TechLab Inc, Blacksburg, VA).

102 Fecal DNA Extraction/16S rRNA Gene V4 region sequencing

- 103 DNA from patient fecal samples was extracted using the QIAamp DNA Stool Mini Kit (catalog
- no. 51504, Qiagen, Hilden, Germany). For each sample, the V4 region of the 16S rRNA gene was
- amplified using the dual indexing sequencing strategy as described previously (15). Sequencing
- 106 was done on the Illumina MiSeq platform, using a MiSeq Reagent Kit V2 500 cycles (Illumina
- 107 cat# MS102-2003), according to the manufacturer's instructions with modifications found in the
- 108 Schloss SOP: https://github.com/SchlossLab/MiSeq_WetLab_SOP. The mock community
- 109 ZymoBIOMICS Microbial Community DNA Standard (Zymo Research cat# D6306) was
- 110 sequenced to monitor sequencing error.

111 **16 S rRNA Gene Amplicon Curation and Analysis**

- 112 The 16S data curation and analysis from the human stool samples was performed using R
- version 4.0.3. Sequences were curated using the R package DADA2 version 1.18 (16). Briefly,
- 114 reads were filtered and trimmed using standard parameters outlined in the DADA2v 1.8

115	pipeline. The error rates for the amplicon datasets were determined using the DADA2's
116	implementation of a parametric error model. Samples were then dereplicated and sequence
117	and variants were inferred. Overlapping forward and reverse reads were merged and
118	sequences that were shorter than 251 bp or longer than 255 bp were removed. Finally,
119	chimeras were removed. Taxonomy was assigned to amplicon sequence variants (ASVs) using
120	the DADA2- formatted SILVA taxonomic training data release 132 (17). Samples with less than
121	16,000 reads per sample were removed from the analysis (this included the extraction blank).
122	The sequences associated with this analysis will be deposited in the SRA. Following sequence
123	curation, the packages phyloseq v1.34.0, vegan v2.5.7, dplyer v1.0.6 and ggpubr v0.4.0 were
124	used for analysis and generation of figures (18).
125	Statistical Methods
126	All statistical comparisons and graphs were made using GraphPad Prism 9 or using R version
127	4.0.3. Comparisons of CDT positive and CDT negative patient demographics, Toxin A/B status
128	and disease outcomes were calculated using Chi-square test. Differences in white blood cell
129	counts (WBC), clinical PCR cycle threshold (Ct) values, stool lactoferrin, days in the ICU and days
130	hospitalized between CDT positive and CDT negative patients were calculated using a Mann-
131	Whitney U test. Differences between Simpson and Shannon indexes were found using a
132	Wilcoxon signed-rank test. A p-value greater than 0.05 was considered significant.
133	

135 **Patient Characteristics**

136	Of the 215 patient stool samples analyzed, 32 were positive for CDT protein (Table 1). Nine of
137	the 32 were negative in the A/BII ELISA. Both CDT positive and CDT negative cohorts were split
138	evenly by sex, and there was no significant difference in age (p=0.1005). CDT positive patients
139	were more likely to also be positive for Toxins A/B (p = 0.0006) and have a WBC count higher
140	than 15,000/ μ l (p=0.0019). Patients testing positive for CDT were also more likely to be
141	admitted to the ICU (p=0.0113) and more likely to die within 90 days of diagnosis (p=0.0320).
142	Patients testing positive for CDT had increased bacterial burden, white blood cell count and
143	intestinal inflammation
144	The 32 CDT positive patients had significantly higher WBC (p=0.0129, Figure 1a). These patients
145	also had higher bacterial burden, as indicated by lower Ct value (p=0.0008, Figure 1b). Of the
146	32 CDT positive patients, 9 were toxin A/B negative. When we compared bacterial burden from
147	the samples that were discordant for the three toxins (CDT positive, negative for toxin A/B) to
148	the burden in the 23 patients that tested positive for both CDT and toxins A/B, those that were
149	positive for all toxins had significantly lower Ct values (Figure S1, p=0.0096). Thus, patients with
150	CDT positive, toxin A/B positive samples had higher <i>C. difficile</i> burden compared to patients
151	positive for CDT and negative for toxin A/B. Patients testing positive for CDT trended to have
152	higher lactoferrin levels compared to CDT negative patients (p=0.0646, Figure 1c).
153	CDT positive patients had increased hospital and ICU stays
154	Of the 215 CDI patients, the CDT positive patients had longer hospitalizations (p=0.0468) and
155	days in the ICU (p=0.0083, Figure 2). Patients testing positive for CDT stayed in the hospital 6.5
156	days longer than CDT negative patients. CDT negative patients stayed in the ICU on average
157	1.73 days compared to 3.59 days for CDT positive patients.

158	No differences in gut microbiome alpha diversity between CDT positive and negative patients
159	We sought to determine if the structure of the fecal microbiome was altered in CDT+ patients.
160	Composition of the fecal microbiota from 172 patients was profiled using amplicon sequencing
161	of the 16S rRNA gene V4 region. While CDT negative patients trended towards slightly
162	increased alpha diversity as measured by either Simpson diversity index or Shannon diversity,
163	there was not a significant difference using either metric (Figure 3a, p=0.26, Figure 3b, p=0.16).
164	
165	Discussion
166	Previous studies have shown that infection with strains positive for the CDTb gene result in
167	increased disease severity, increased disease recurrence and higher mortality rates (2, 11-13).
168	Here we reiterate those earlier findings and further show that patients with CDT protein
169	present in stool (9/32 (28%) of which had no detectable toxin A/B production) had worse
170	disease outcomes, with increased rates of ICU admissions and higher mortality. Additionally,
171	these patients had longer stays in the hospital and ICU, causing increased burden to health care
172	systems.
173	Other measures of disease severity were also worse in CDT+ infections. One characteristic of
174	severe CDI is having a WBC count of greater than 15,000/ μ l (19). We found that 45.2% of CDT
175	positive patients were considered to have severe CDI based on this guideline compared to
176	19.5% of CDT negative patients. Overall CDT positive patients had higher WBC counts
177	(p=0.0129). Other groups have similarly found that patients infected with <i>C. difficile</i> strains
178	encode for CDT have elevated WBC count (2, 11, 12). We did not find any significant differences
179	in neutrophils, eosinophils, lymphocytes, monocytes, or basophils, although our data set was

180	incomplete for these values. Patients with CDT positive stools also exhibited higher bacterial
181	burdens as indicated by lower Ct values (p=0.0008) consistent with higher burden being
182	correlated with more severe disease (13, 20). We also found that CDT positive, toxin A/B
183	positive patients had lower Ct values compared to CDT positive, toxin A/B negative (p=0.0096),
184	even though measures in clinical disease did not differ. Boone et al found that patients with the
185	CDT producing hypervirulent ribotype 027 had increased lactoferrin compared to patients
186	colonized with other strains (21). We confirmed the earlier finding that CDT positive patients
187	had higher lactoferrin levels, although in our instance this was not statistically significant
188	(p=0.06).
189	Lastly, we performed 16 S rRNA gene sequencing to determine if there were differences in gut
190	microbiome diversity in CDT positive and negative patients. Studies have described a decreased
191	gut microbiome diversity in patients with CDI compared to control patients (22-24). We found
192	no significant differences in Simpson or Shannon indexes, although CDT positive patients
193	tended towards having lower microbiome diversity. These results indicate that increased
194	disease severity related to CDT is not associated with decreased gut microbiome diversity.
195	In conclusion, we believe we are the first to demonstrate that patients with stool testing
196	positive for CDT by ELISA have more severe CDI and worse disease outcomes. The presence of
197	stool CDT was associated with higher bacterial burden and WBC counts, as well as longer
198	hospital and ICU stays and increased mortality. There was no significant difference in gut
199	microbiome diversity between CDT positive and negative patients. Testing for the presence of
200	CDT in stool is a valuable tool to better explain differences in disease severity amongst CDI

- 201 patients. Detection of CDT and CDT-expressing strains may be beneficial in disease diagnosis
- 202 and treatment.
- 203
- 204 Acknowledgments
- 205 We would like to thank Jennifer White for IRB protocol preparation, and Research & Clinical
- 206 Trial Analytics, Ken Scully, and Li Mo for clinical data retrieval.
- 207 Funding
- 208 This work was funded by National Institutes of Health (R01 AI124214-05 to W.A.P.,
- 209 K23AI163368 to G.R.M., F32DK124048 to J.L.L.) and National Center for Advancing Translational
- 210 Science (UL1TR003015, KL2TR003016).
- 211 Conflicts of Interest
- 212 W.A.P. is a consultant for TechLab Inc and R.J.C and M.W.L. are TechLab Inc employees. All
- 213 other authors declare no conflict of interest.
- 214

- 216
- 217
- 218
- 219
- 220
- 221
- 222

223 References

- Centers for Disease Control and Prevention. 2019. Antibiotic Resistance Threats In The
 United States.
 Bacci S, Molbak K, Kjeldsen MK, Olsen KE. 2011. Binary toxin and death after Clostridium
- 227 difficile infection. Emerg Infect Dis 17:976-82.
- 228 3. Gerding DN, Johnson S, Rupnik M, Aktories K. 2014. Clostridium difficile binary toxin
- 229 CDT: mechanism, epidemiology, and potential clinical importance. Gut Microbes 5:15-
- 230 27.
- 231 4. Cowardin CA, Buonomo EL, Saleh MM, Wilson MG, Burgess SL, Kuehne SA, Schwan C,
- 232 Eichhoff AM, Koch-Nolte F, Lyras D, Aktories K, Minton NP, Petri WA, Jr. 2016. The
- binary toxin CDT enhances Clostridium difficile virulence by suppressing protective
- colonic eosinophilia. Nat Microbiol 1:16108.
- 235 5. Fang FC, Polage CR, Wilcox MH. 2017. Point-Counterpoint: What Is the Optimal
- Approach for Detection of Clostridium difficile Infection? J Clin Microbiol 55:670-680.
- 237 6. Koo HL, Van JN, Zhao M, Ye X, Revell PA, Jiang ZD, Grimes CZ, Koo DC, Lasco T, Kozinetz
- 238 CA, Garey KW, DuPont HL. 2014. Real-time polymerase chain reaction detection of
- asymptomatic Clostridium difficile colonization and rising C. difficile-associated disease
- 240 rates. Infect Control Hosp Epidemiol 35:667-73.
- 241 7. Moehring RW, Lofgren ET, Anderson DJ. 2013. Impact of change to molecular testing for
- 242 Clostridium difficile infection on healthcare facility-associated incidence rates. Infect
- 243 Control Hosp Epidemiol 34:1055-61.

244 O. FUIDE CO. UVUINE CL. NEIHIEUV IVIA, LESHE JL. CHIII DL. WAIIE J. NEUVEH HHI, HUG	244 8	8.	Polage CR.	Gvorke CE.	. Kennedv MA	. Leslie JL.	Chin DL	. Wang S.	Nguven HH	. Huang	В
-----------------------------------------------------------------------------------------	-------	----	------------	------------	--------------	--------------	---------	-----------	-----------	---------	---

- 245 Tang YW, Lee LW, Kim K, Taylor S, Romano PS, Panacek EA, Goodell PB, Solnick JV,
- 246 Cohen SH. 2015. Overdiagnosis of Clostridium difficile Infection in the Molecular Test
- 247 Era. JAMA Intern Med 175:1792-801.
- 248 9. Dallal RM, Harbrecht BG, Boujoukas AJ, Sirio CA, Farkas LM, Lee KK, Simmons RL. 2002.
- Fulminant Clostridium difficile: an underappreciated and increasing cause of death and
 complications. Ann Surg 235:363-72.
- 251 10. Polage CR, Chin DL, Leslie JL, Tang J, Cohen SH, Solnick JV. 2012. Outcomes in patients
- tested for Clostridium difficile toxins. Diagn Microbiol Infect Dis 74:369-73.
- 253 11. Barbut F, Gariazzo B, Bonne L, Lalande V, Burghoffer B, Luiuz R, Petit JC. 2007. Clinical
- 254 features of Clostridium difficile-associated infections and molecular characterization of
- 255 strains: results of a retrospective study, 2000-2004. Infect Control Hosp Epidemiol
- 256 28:131-9.
- 257 12. Berry CE, Davies KA, Owens DW, Wilcox MH. 2017. Is there a relationship between the
- 258 presence of the binary toxin genes in Clostridium difficile strains and the severity of C.
- 259 difficile infection (CDI)? Eur J Clin Microbiol Infect Dis 36:2405-2415.
- 260 13. Carman RJ, Daskalovitz HM, Lyerly MW, Davis MY, Goodykoontz MV, Boone JH. 2018.
- 261 Multidrug resistant Clostridium difficile ribotype 027 in southwestern Virginia, 2007 to
- 262 2013. Anaerobe 52:16-21.
- 263 14. Carman RJ, Stevens AL, Lyerly MW, Hiltonsmith MF, Stiles BG, Wilkins TD. 2011.
- 264 Clostridium difficile binary toxin (CDT) and diarrhea. Anaerobe 17:161-5.

265	15.	Kozich JJ, Westcott SL, Baxter NT, Highlander SK, Schloss PD. 2013. Development of a
266		dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence
267		data on the MiSeq Illumina sequencing platform. Appl Environ Microbiol 79:5112-20.
268	16.	Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. 2016. DADA2:
269		High-resolution sample inference from Illumina amplicon data. Nat Methods 13:581-3.
270	17.	Pruesse E, Quast C, Knittel K, Fuchs BM, Ludwig W, Peplies J, Glockner FO. 2007. SILVA: a
271		comprehensive online resource for quality checked and aligned ribosomal RNA
272		sequence data compatible with ARB. Nucleic Acids Res 35:7188-96.
273	18.	McMurdie PJ, Holmes S. 2013. phyloseq: an R package for reproducible interactive
274		analysis and graphics of microbiome census data. PLoS One 8:e61217.
275	19.	McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER,
276		Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH. 2018.
277		Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017
278		Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare
279		Epidemiology of America (SHEA). Clin Infect Dis 66:e1-e48.
280	20.	Kamboj M, Brite J, McMillen T, Robilotti E, Herrera A, Sepkowitz K, Babady NE. 2018.
281		Potential of real-time PCR threshold cycle (CT) to predict presence of free toxin and
282		clinically relevant C. difficile infection (CDI) in patients with cancer. J Infect 76:369-375.
283	21.	Boone JH, DiPersio JR, Tan MJ, Salstrom SJ, Wickham KN, Carman RJ, Totty HR, Albert
284		RE, Lyerly DM. 2013. Elevated lactoferrin is associated with moderate to severe
285		Clostridium difficile disease, stool toxin, and 027 infection. Eur J Clin Microbiol Infect Dis
286		32:1517-23.

287	22.	Milani C, Ticinesi A, Gerritsen J, Nouvenne A, Lugli GA, Mancabelli L, Turroni F, Duranti S,
288		Mangifesta M, Viappiani A, Ferrario C, Maggio M, Lauretani F, De Vos W, van Sinderen
289		D, Meschi T, Ventura M. 2016. Gut microbiota composition and Clostridium difficile
290		infection in hospitalized elderly individuals: a metagenomic study. Sci Rep 6:25945.
291	23.	van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE,
292		Kuijper EJ, Bartelsman JF, Tijssen JG, Speelman P, Dijkgraaf MG, Keller JJ. 2013.
293		Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med
294		368:407-15.
295	24.	Han SH, Yi J, Kim JH, Lee S, Moon HW. 2019. Composition of gut microbiota in patients
296		with toxigenic Clostridioides (Clostridium) difficile: Comparison between subgroups
297		according to clinical criteria and toxin gene load. PLoS One 14:e0212626.
298		
299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317		
318		

319 Table 1. Patient Characteristics

320	Figure 1. Patients testing positive for CDT had increased bacterial burden, white blood cell
321	count and intestinal inflammation. (a) Patients with CDT-expressing strains had higher white
322	blood cell counts than patients with non-CDT expressing strains (p=0.0129). (b) CDT positive
323	patients had lower Ct values than CDT negative patients, indicating increased bacterial burden
324	(p=0.0008). (c) CDT positive patients had elevated lactoferrin comparted to CDT negative
325	patients, although not statistically significant (p=0.0646)
326	Figure 2. CDT positive patients had increased hospital and ICU stays. (a) Patients with CDT
327	detected in their stool had longer stays in the hospital, with an average stay of 18 days
328	compared to 11.5 days for CDT negative patients. (p=0.0468). (b) CDT positive patients had
329	longer stays in the ICU (p=0.0083).
330	Figure 3. No differences in gut microbiome diversity between CDT positive and negative
331	patients (a) There was no significant difference in Simpson Diversity Index between CDT
332	positive and negative patients (p=0.26). (b) Shannon Diversity Index was slightly higher in CDT
333	negative patients although not statistically significant (p=0.16).
334	Supplemental Figure 1. Higher bacterial burden in CDT positive, toxin A/B positive patients
335	compared to patients positive for CDT and negative for toxin A/B. CDT and toxin A/B positive
336	(n=23) had lower Ct values compared to CDT positive, toxin A/B negative patients (p=0.0096)
337	
338	
339	
340	
341	
342 242	
343 344	







Characteristic	CDT+ (32)	CDT- (183)	p value
Age (mean, SD)	64.7 (16.2)	59.0 (17.0)	0.1005
Sex (No, %)*			0.9258
Female	16 (50)	85 (50.1)	
Male	16 (50)	82 (49.9)	
Toxin A/B+ (No, %)	23 (71.9)	72 (39.3)	0.0006
WBC > 15,000/µl (No, %) *	14 (45.2)	34 (19.5)	0.0019
Admitted to ICU (No, %) *	11 (34.4)	28 (15.6)	0.0113
Deceased within 90 days of diagnosis (No, %) *	7 (23.3)	16 (9.6)	0.0320

*Some clinical data missing, percentage based on patients with data available